UBS Group’s Alterity Therapeutics ATHE Stock Holding History

UBS Group’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-63	Closed	-$6K	–	8786
2014 Q4	$6K	Buy	+63	New	+$6.81K	﹤0.01%	8800

Other funds holding ATHE

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

TLCM

Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $3.28B AUM 23.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's ATHE Position: Q2 2025 in Review

UBS Group sold out of Alterity Therapeutics (ATHE) in Q2 2025, closing a stake of 13,004 shares — an estimated $44.9K sold.

UBS Group first reported a position in ATHE in Q4 2014 and held it in 33 quarters. The position peaked at $63K in Q2 2020. 11 funds tracked by Wall St. Rank hold ATHE as of Q2 2025.

UBS Group reported no remaining Alterity Therapeutics position as of Q2 2025 after selling out during the quarter.
UBS Group sold 13,004 Alterity Therapeutics shares in Q2 2025, an estimated $44.9K.
UBS Group first reported a position in Alterity Therapeutics in Q4 2014 and held it in 33 quarters.
UBS Group's Alterity Therapeutics position peaked at $63K in Q2 2020.
11 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.